Orforglipron liver safety profile — my results so far

DebRD_ATL said:

The version of this that has an answer is narrower than the version being asked.

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

andrew_nyc said:

The manufacturing argument is the underrated one.

Genuinely useful, thank you. I had the facts and not the framework.

DebRD_ATL said:

The version of this that has an answer is narrower than the version being asked.

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Correct me if the detail matters more than I have assumed.

Moderator note: the sourcing question belongs in the vendor section and has been split out.